J. D. Wolchok - Researcher Profile | RDL Research Database

Publications

2 shown

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

J. D. Wolchok , L. Thomas , I. N. Bondarenko +7 more

LBA5 Background: IPI monotherapy (3mg/kg) improved overall survival (OS) in a phase III study of previously treated, unresectable or metastatic melanoma. Current study in 1st li...

2011 Journal of Clinical Oncology 13 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Mario Sznol , John D. Powderly , David C. Smith +7 more

2506 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a fully human IgG4 PD-1 blocking antibody, has shown antitum...

2010 Journal of Clinical Oncology 84 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 97
Institution: Bristol-Myers Squibb (Belgium)

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.